$0.6049
0.004900.82%
At close: -
$0.5921
-0.01-2.12%
After Hours: 5:03 PM EDT
Comments
Loading...
Adaptimmune Therapeutics (NASDAQ:ADAP) Stock, Earnings Estimates, EPS, And Revenue
Adaptimmune Therapeutics reports earnings on a quarterly basis. These quarterly earnings reports give investors a glimpse into financial results from a company for a 3 month period. Earnings reports almost always include EPS and Revenue results.
Earnings Date
Mar 5
EPS Estimate
$-0.160
Quarterly Revenue Estimate
$9.9M
Annual Revenue
(as of Sep 30)
(as of Sep 30)
$175M
Analyze the earnings history of Adaptimmune Therapeutics using advanced sorting and filters.
Data brought to you by Benzinga APIs
Adaptimmune Therapeutics (ADAP) Earnings Per Share
Quarterly Earnings Surprise Amount
| Fiscal Quarter End | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Sep 2024 | 2024-11-13 | $-0.07 | $-0.13 | 46.2 % |
| Jun 2024 | 2024-08-12 | $0.24 | $-0.08 | 400.0 % |
| Mar 2024 | 2024-05-15 | $-0.18 | $-0.10 | -80.0 % |
| Dec 2023 | 2024-03-06 | $-0.24 | $-0.10 | -140.0 % |
Adaptimmune Therapeutics (ADAP) Revenue
Quarterly Revenue Surprise Amount
| Fiscal Quarter End | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Sep 2024 | 2024-11-13 | $40.90M | $11.17M | 266.2 % |
| Jun 2024 | 2024-08-12 | $128.23M | $38.48M | 233.2 % |
| Mar 2024 | 2024-05-15 | $5.68M | $10.73M | -47.1 % |
| Dec 2023 | 2024-03-06 | $231.00K | $20.47M | -98.9 % |
FAQ
When is Adaptimmune Therapeutics (NASDAQ:ADAP) reporting earnings?
Adaptimmune Therapeutics (ADAP) is scheduled to report earnings on March 5, 2025. The last reported earnings were for reported on November 13, 2024 for Q3.
What were the latest earnings per share (EPS) for Adaptimmune Therapeutics (NASDAQ:ADAP)?
The Actual EPS was $-0.07, which beat the estimate of $-0.13.
What were Adaptimmune Therapeutics’s (NASDAQ:ADAP) revenues?
The Actual Revenue was $40.9M, which beat the estimate of $11.2M.
Browse earnings estimates, EPS, and revenue on all stocks.